MentionFox
Home › Executive changes › Kiniksa Pharmaceuticals International, plc
Leadership changes · SEC Form 8-K, Item 5.02

Kiniksa Pharmaceuticals International, plc executive changes

Every leadership change Kiniksa Pharmaceuticals International, plc reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings1
Departures named2
Latest filing2026-05-01

Kiniksa Pharmaceuticals International, plc filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-05-01. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-05-01 · 8-K

Departing: Eben Tessari, Chief Strategy Officer

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.

Departing: Eben Tessari

Mr. Tessari will leave the Company on May 15, 2026 and will become a consultant to the Company and an advisor to its Science and Research Committee.
Hiring for a seat like this?

Find people with the same kind of experience as the Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc, with the record behind each one.

Find candidates like Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc
Selling to Kiniksa Pharmaceuticals International, plc?

New leaders review vendors and budgets in their first months. Get an alert the next time Kiniksa Pharmaceuticals International, plc is in the news or changes leadership.

Get an alert when Kiniksa Pharmaceuticals International, plc changes leadership

Tools for this story

Each opens in a new tab, filled in for Kiniksa Pharmaceuticals International, plc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/kiniksa-pharmaceuticals-international
Last updated 2026-09-27
Primary record: SEC filing
Kiniksa Pharmaceuticals International, plc (KNSA) executive changes: Eben Tessari departs, Chief Strategy Officer. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/kiniksa-pharmaceuticals-international